

## REMARKS

The Sequence Listing has been corrected to include peptides recited in Tables 8 and 10-11 as indicated in the Examiner's note in the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures. The Specification has been amended to include sequence identifiers for the peptides recited in Tables 8 and 10-11. Peptides disclosed in Tables 3, 9, 12, and 13 of the Specification have been identified by the Amendment filed January 7, 2000 (copy attached). Attached hereto is a marked-up version of the changes made to the Specification by the current amendment. The page is entitled: "**Version with markings to show changes made**".


The undersigned hereby states that the computer readable form copy (CRF copy) of the substitute Sequence Listing and the paper copy of the substitute Sequence Listing, submitted in accordance with 37 C.F.R. § 1.825(a) and (b), respectively, are the same and contain no new matter. Accordingly, entry of the substitute Sequence Listing into the above-captioned case is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. 399632001920. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: December 4, 2002

By:



Bruce D. Grant  
Registration No. 47,608

Morrison & Foerster LLP  
3811 Valley Centre Drive  
Suite 500  
San Diego, California 92130-2332  
Telephone: (858) 720-7962  
Facsimile: (858) 720-5125



## VERSION WITH MARKINGS TO SHOW CHANGES MADE

### In the Specification:

The paragraph beginning at page 58, line 30, has been amended as follows:

HLA-A3.2 Allele-Specific Motif (SEQ ID NO:378)

The paragraph beginning at page 59, line 30, has been amended as follows:

HLA-A11 Allele-Specific Motif (SEQ ID NO:379)

The paragraph beginning at page 60, line 13, has been amended as follows:

HLA-A24.1 Allele-Specific Motif (SEQ ID NO:380)